Vol 3, No 4 (2017)
Review paper
Published online: 2018-03-01

open access

Page views 2997
Article views/downloads 32777
Get Citation

Connect on Social Media

Connect on Social Media

Comprehensive treatment of herpes simplex virus

Aleksandra Lesiak12, Joanna Narbutt12
Forum Dermatologicum 2017;3(4):147-151.

Abstract

Herpes simplex virus infection has been accompanying people for thousands of years. This disease was already described by the ancient Egyptians. The most common clinical form of HSV infection is still herpes labialis, mainly caused by the HSV-1 virus. Research conducted in the middle of the last century allowed to conclude that type 1 of the virus most often causes infections above the waist, while type 2 of herpes virus — infection in anogenital area and meningitis. Despite the views among patients that herpes, or ‘cold’, is a relatively trivial disease, in our opinion it is justified to treat this disease entity. First; implementation of the therapy shortens the duration of the disease, which reduces the stress associated with the cosmetic defect of the occurrence of changes within the lip. Secondly; the use of treatment also reduces subjective symptoms such as tingling, pain or burning. The drug most often used in the treatment of herpes is acyclovir, effective especially in inhibiting HSV replication. Nevertheless, from a comprehensive physician’s point of view and on the basis of objective data, the use of combination therapy, i.e. the administration of a general drug containing acyclovir and the simultaneous use of topical treatment leads to shortening of the disease duration as well as reducing pain. The oral drug effectively inhibits the replication of the HSV virus and reduces the frequency of relapses, and local treatment with acyclovir relieves skin changes and reduces the risk of their spread.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Costello M, Sabatini L, Yungbluth P. Herpes Simplex Virus infections and current methods for laboratory detection. Clin Microbiol Newsl. 2006; 28: 185–192.
  2. Smith JS, Herrero R, Bosetti C, et al. International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002; 94(21): 1604–1613.
  3. Anzivino E, Fioriti D, Mischitelli M, et al. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. Virol J. 2009; 6: 40.
  4. Żaba R. Opryszczka, półpasiec, ospa wietrzna. Wydawnictwo Termedia. Poznań 2011, rozdział III : 45–83.
  5. Logan HL, Lutgendorf S, Hartwig A, et al. Immune, stress, and mood markers related to recurrent oral herpes outbreaks. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86(1): 48–54.
  6. Rosen T. Recurrent Herpes Labialis in Adults: New Tricks for an Old Dog. J Drugs Dermatol. 2017; 16(3): s49–s53.
  7. Wolf R, Wolf D, Ruocco V. The benefits of smoking in skin diseases. Clin Dermatol. 1998; 16(5): 641–647.
  8. Braun-Falco O, Pelwig G, Wolf H, Burgdorf WHC. Dermatologia. Wydawnictwo Czelej, Lublin, 2002, tom I : 59–68.
  9. Cieśluk B, Majewska A. Wirus opryszczki pospolitej typu I (HSV-1) – epidemiologia i kliniczne postacie nietypowych zakażeń. Zakażenia. 2006; 6: 71–72.
  10. Majewska A, Krawczyk E, Łuczak M. Opryszczka narządów płciowych (genital herpes) – obraz kliniczny i możliwe następstwa zakażenia. Zakażenia 2005;5: 61-62. : 64–66.
  11. Majewska A, Łuczak M. Wirusy opryszczki pospolitej – wczoraj i dziś. Przegl Dermatol. 2008; 95: 585–587.
  12. Enright AM, Prober CG. Herpesviridae infections in newborns: varicella zoster virus, herpes simplex virus, and cytomegalovirus. Pediatr Clin North Am. 2004; 51(4): 889–908, viii.
  13. Figlerowicz M. Najczęstsze postacie kliniczne zakażeń wywołanych przez wirusy z rodziny Herpesviridae. Prze Lek. 2006; 8: 61–67.
  14. Jabłońska S, Majewski S. Choroby skóry i choroby przenoszone drogą płciową. PZWL, Warszawa 2008.
  15. Mroczkowski TF, Teofoli P, Ferranti G. Opryszczka narządów płciowych. In: Choroby przenoszone drogą płciową. Czelej, Lublin : 183–206.
  16. Peterslund NA. Herpesvirus infection: an overview of the clinical manifestations. Scand J Infect Dis Suppl . 1991; 80: 15–20.
  17. Wysocki J, Salamon-Słowińska D. Zakażenie wirusami Herpes simplex – postaci kliniczne i ich leczenie. Zakażenia. 2003; 3: 62–67.
  18. Rudolph CM, Müllegger RR, Schuller-Petrovic S, et al. Unusual herpes simplex virus infection mimicking foreign body reaction after cosmetic lip augmentation with expanded polytetrafluoroethylene threads. Dermatol Surg. 2003; 29(2): 195–197.
  19. Dougherty AL, Rashid RM, Bangert CA. Angioedema-type swelling and herpes simplex virus reactivation following hyaluronic acid injection for lip augmentation. J Am Acad Dermatol. 2011; 65(1): e21–e22.
  20. Dzieciątkowski T, Rola A, Majewska A, et al. Leki stosowane w leczeniu zakażeń herpeswirusami ludzi. Post Mikrobiol. 2007; 3: 211–221.
  21. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008; 168(11): 1137–1144.
  22. Hull C, McKeough M, Sebastian K, et al. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol. 2009; 23(3): 263–267.
  23. Hull CM, Harmenberg J, Arlander E, et al. ME-609 Study Group. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011; 64(4): 696.e1–696.11.
  24. Bieber T, Chosidow O, Bodsworth N, et al. LIP Study Group. Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014; 13(7): 791–798.